Teachers Retirement System of The State of Kentucky decreased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 7.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,305,850 shares of the company’s stock after selling 175,500 shares during the period. Teva Pharmaceutical Industries accounts for 0.6% of Teachers Retirement System of The State of Kentucky’s investment portfolio, making the stock its 20th biggest position. Teachers Retirement System of The State of Kentucky’s holdings in Teva Pharmaceutical Industries were worth $91,311,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 1.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock valued at $1,561,120,000 after acquiring an additional 500,000 shares in the last quarter. WCM Investment Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. Wellington Management Group LLP increased its position in Teva Pharmaceutical Industries by 5.8% during the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after purchasing an additional 419,329 shares in the last quarter. Janus Henderson Group PLC increased its position in Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock worth $145,076,000 after purchasing an additional 72,880 shares in the last quarter. Finally, Swiss National Bank raised its stake in Teva Pharmaceutical Industries by 28.7% in the 1st quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock valued at $127,344,000 after purchasing an additional 941,700 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, CEO Richard Francis sold 250,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the completion of the transaction, the chief executive officer owned 927,529 shares of the company’s stock, valued at $39,178,824.96. This represents a 21.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The SEC filing for this sale provides additional information. Insiders have sold 715,945 shares of company stock worth $29,061,351 over the last ninety days. Insiders own 0.54% of the company’s stock.
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same period in the prior year, the firm posted $0.78 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have issued reports on TEVA. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They issued a “buy” rating and a $52.00 target price on the stock. Zacks Research downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. TD Cowen boosted their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Finally, Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an “overweight” rating in a research note on Thursday, November 12th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $48.15.
View Our Latest Research Report on TEVA
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Featured Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
